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Background: Although sclerotherapy is a common treatment for benign oral vascular lesions, there is no well-
standardized protocol for this purpose. The aim of the present study was to describe the clinical characteristics of 
patients treated by sclerotherapy with ethanolamine oleate (EO), in order to contribute to a better understanding 
of this technique.
Material and Methods: Medical records and images of 90 patients treated by the same sclerotherapy protocol were 
retrieved and analysed. Thus, 43 cases with complete information were selected and described. 
Results: The most affected age group was 41–70 years, with a female predominance and 86% of patients being 
Caucasian. Lips were the most affect site (70%) followed by the tongue (16%). Regarding clinical appearance, 
approximately 90% of lesions were classified as nodules, and 90% of patients reported no pain. Approximately 
40% of lesions were 0.5–1.0 cm in size. In 58% of the patients, only one application of ethanolamine oleate was 
necessary. The application doses varied according to the lesion size and number of applications. Complete clinical 
regression occurred in 91% of cases, whereas 9% showed partial regression.
Conclusions: Sclerotherapy with EO is an acceptable, effective and affordable treatment for benign oral vascular 
lesions. 
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Introduction  
Hemangiomas and vascular malformations are benign le-
sions of blood vessels relatively common in the head and 
neck region. More than 60% of all hemangiomas occur in 
these areas, and the most affected oral regions are the lips, 
tongue, buccal mucosa, gums, and palate. There is a higher 
prevalence in females (65%), twins and preterm infants (1-
3). Vascular lesions are usually asymptomatic, varies in 
size from a few millimetres to several centimetres, and 
can lead to facial asymmetries. The colour ranges from 
red to purple, according to the location and depth of tissue 
invasion, as well as the degree of vascular congestion of 
the affected area (4). It can present as a flat or raised lesion 
with a smooth or nodular surface, defined edges, sessile or 
pedunculated and a soft consistency on palpation. 
In contrast to hemangiomas and vascular malformations, 
oral varices are more frequent in adults over 60 years. Age 
is a predisposing factor, as is the loosening of tissue and 
increase in venous pressure. Sublingual varices are the 
most common type and appear as bluish-purple single or 
multiple nodules in the ventral-lateral border of the tongue. 
Although less frequent, varices can also occur in the lips 
and other regions of the oral mucosa (5,6). 
The diagnosis of oral vascular lesions is based on the clini-
cal characteristics and history of the lesion. Diascopy, as-
piration of the lesion and imaging exams may also contrib-
ute to diagnosis and treatment planning in some cases. In 
addition, important findings such as the hemodynamics of 
the lesion (high or low blood flow) should be considered 
for the treating practice (7-10).
Surgical excision is one of the most used treatments, espe-
cially for small lesions. However, before this option is se-
lected, some problems must be considered, such as bleed-
ing, incomplete resection and aesthetic problems (11-13). 
Alternative methods are mentioned in the literature, in-
cluding laser surgery, cryotherapy, chemotherapy agents, 
corticosteroids, embolization and sclerotherapy (13-19).
The mechanism of action of sclerotherapy involves the 
substitution of the vascular component by a fibrotic tissue 
in response to an inflammatory process. Although sclero-
therapy is one of the most versatile and advantageous 
treatments, the concentration of the sclerosing agent, dose 
and mode of application are not properly standardized. 
This applies to a wide variety of techniques and protocols, 
making the decision to use this treatment option extremely 
difficult. The development of a protocol must respect the 
morphological and functional uniqueness of each lesion 
in order to define an appropriate dosage of the sclerosing 
agent to be used (11).
Thus, the aim of the present study was to describe the clin-
ical characteristics of patients with oral vascular lesions 
treated by sclerotherapy in a single institution, in order to 
contribute to a better understanding of this technique that 
still has no well-established protocol in the scientific lit-
erature.
Material and Methods
Medical records and images of patients with oral vas-
cular lesions treated by sclerotherapy were retrieved for 
the period between 1990 and 2010. Patient information 
and images were analysed and data regarding age, gen-
der, skin colour, type and period of complaint, clinical 
diagnosis hypothesis, symptomatology, location, size 
and clinical appearance of the lesion, treatment and out-
comes were collected. 
The same treatment protocol with a concentration of 
5% pure ethanolamine oleate (EO) (Ethamolin®, Zest 
Pharma Ltda., Rio de Janeiro, RJ) was applied in all 
lesions. The following sclerotherapy protocol was ap-
plied: a) the patients were informed regarding the treat-
ment and probable discomfort after the procedure and 
their consent were obtained; b) The dose of EO was 
calculated according to the size of the lesion. For le-
sions smaller than 1.0 cm, only one application of 0.3 
ml of EO was planned. For larger lesions, the size was 
multiplied in cm by 0.3 ml. Furthermore, for larger le-
sions, more sessions were often necessary and the total 
dose was divided among the total number of sessions; c) 
anaesthetic infiltration with a vasoconstrictor was per-
formed around the lesion; d) with an insulin syringe, the 
EO was applied in the centre and in the deepest portion 
of the lesion. For larger lesions, more than one puncture 
point was made to distribute the sclerosing agent homo-
geneously. e) analgesic was prescribed for the following 
2 days; f) the patients were evaluated after one week; g) 
the procedures were repeated at 3-week intervals until a 
satisfactory result was obtained.
This present study was conducted in accordance with 
ethical principles and was approved by the Research 
Ethics Committee (protocol 083/2013; 09/10/2013).
- Statistical analysis
The lesions were divided into 3 groups which values 
represented the average size of the lesions. The statisti-
cal analysis was done using chi-squared test through the 
software MedCalc (Version 11.6.1.0, Mariakerke, Bel-
gium) with a significance level of 5%.
Results
A total of 90 patients treated by sclerotherapy using EO 
were retrospectively identified. However, in 47 (52.%) 
of cases, detailed information regarding the doses of the 
applications was not total available in the medical re-
cords. Thus, 43 cases with complete information were 
selected and described. 
The most affected age group was between 41 and 70 
years (mean age: 47 years, range: 4-87 years). The female 
gender was predominant (56%), and 86% of patients were 
Caucasian. Half of the patients reported the presence of 
a lesion (complaint period) lasting longer than 5 years. 
Regarding the location, there was a higher rate of occur-
rence on the lips (70%) followed by the tongue (16%) and 
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buccal mucosa (14%). According to the clinical appear-
ance of the lesions, approximately 90% were classified 
as nodules. A total of 41% of the lesions were between 
0.5 cm and 1.0 cm in size (Table 1). Swelling was the 
most common type of complaint, reported by 28 patients 
(65%) followed by colour alteration (7 patients, 16%). The 
vast majority of patients reported no pain (90%). Con-
cerning the clinical diagnostic hypothesis, 40 lesions 
were defined as hemangiomas and vascular malforma-
tions (93%) and 3 as varices (7%).
Only one session of one application of 5% EO was suf-
ficient to obtain a satisfactory result in 58% of the pa-
tients. The regression of the lesions usually occurred in 
2 to 3 weeks after the application. Regarding the lesions 
n %
Age (years) <10 3 7%
11 a 20 3 7%
21 a 30 3 7%
31 a 40 5 12%
41 a 50 6 14%
51 a 60 9 21%
61 a 70 10 23%
>70 4 9%
Gender Male 19 44%
Female 24 56%
Skin Colour Caucasian 37 86%
Others 6 14%
Complaint period Congenital 1 2%
≤1 month 2 5%
>1 and ≤6 months 2 5%
>6 and ≤12 months 2 5%
>1 and ≤5 years 10 23%
>5 and ≤10 years 6 14%
>10 years 16 37%
Unknown 4 9%
Location Lower lip 21 49%
Upper lip 9 21%
Tongue 7 16%
Buccal mucosa 6 14%
Size (cm) ≤0.5 6 14%
>0.5 and ≤1.0 18 41%
>1.0 and ≤1.5 8 19%
>1.5 and ≤3.0 8 19%
>3.0 3 7%
Total 43 100%
Table I. Distribution of patients treated by sclerotherapy according to age, gender, skin colour, 
period of complaint, location and size of the lesions.
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larger than 1.0 cm, 6 cases received a total dose of 0.4 to 
0.7ml of EO, 9 cases received 0.8 to 2.0 ml and 4 cases 
received more than 2.0 ml. 
A  positive correlation between the number of EO appli-
cations and the total doses administered was observed. 
Of the 20 patients who received a total dose lower than 
1 ml, 75% received only one application. On the other 
hand, of the 23 patients who received a total dose equal 
or higher than 1.0 ml, 52% of these patients required 2 or 
more applications. A relation of the number of applica-
tions with the mean of lesion size and the mean of the 
total dose is shown in Table 2. Moreover, there was a 
positive correlation between the total dose and the size of 
the lesions (p < 0.05) as well as between the number of 
applications and size of the lesions (p < 0.05) (Table 3).
Most patients reported some discomfort following ap-
plication of the sclerosing agent, such as pain, swell-
ing, redness and burning, which lasted from 1 to 3 days. 
However, no important complications were related or 
observed in any case.
The majority of lesions showed good results. Complete 
regression (100% of re-establishment of normal mucosa 
appearance) occurred in 39 patients (91%) (Figs. 1,2). 
Four patients (9%) showed partial regression of the le-
sions, and no subsequent surgery for aesthetic and/
or functional rehabilitation was required (Fig. 3). No 
complications or recurrences were reported during the 
follow-up period. 
Discussion
The classification suggested by the International Soci-
ety for the Study of Vascular Anomalies (ISSVA) (20) is 
based on the fundamental separation of vascular anom-
alies into those lesions with a proliferative component 
Number of applications n (%) Mean lesion size in cm (standard deviation)
Mean total dose in ml 
(standard deviation)
1 26 (60%) 1.16 (± 0.67) 0.8 (± 0.39)
2 9 (21%) 1.35 (± 0.50) 1.15 (± 0.51)
3 3 (7%) 2.06 (± 0.70) 1.71 (± 0.60)
4 3 (7%) 2.4 (± 2.26) 2.85 (± 2.24)
6 2 (5%) 3.5 (± 2.12) 2.75 (± 1.9)
Total 43 (100%) 2.09 1.85
Table 2. Number of cases, mean of lesion size and mean of total dose according to the number of applications.
Table 3. Association of clinical variables with lesion size.
Parameter Lesion Size (cm)       p-value 
 ≤ 1 
n (%) 





Gender     
Male 12 (27.9) 5 (11.6) 2 (4.7)  
Female 12 (27.9) 10 (23.3) 2 (4.7)       0.57 
Age (years)     
≤ 50 10 (23.3) 7 (16.3) 3 (7.0)  
> 50 14 (32.6) 8 (18.6) 1 (2.3)       0.46 
Number of applications     
1 17 (39.5) 8 (18.6) 1 (2.3)  
2 5 (11.6) 4 (9.3) 0 (0.0)                             
≥3 2 (4.7) 3 (7.0) 0 (0.0)       0.03 
Total dose (ml)     
≤0.6 
>0.6 and ≤1.2                                  











       0.004 
 
>1.8 2 (4.7) 2 (4.7) 3 (7.0)  
Results     
Partial regression 2 (4.7) 1 (2.3) 1 (2.3)  
Complete regression 22 (51.2) 14 (32.6) 3 (7.0)        0.51 
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(named “vascular tumours”) versus relatively static 
“vascular malformations”, following Mulliken and 
Glowacki’s seminal work (1). Thus, a significant dispar-
ity between the epidemiological data is still found. In 
oral lesions, the similarity of the clinical characteristics 
of hemangiomas and vascular malformations may make 
difficult the classification and clinical differential diag-
nosis. However, the distinction of these lesions will not 
interfere with the proper administration of treatment in 
these cases (21). In the current study, according to clini-
cal characteristics, 93% of the treated lesions were clini-
cally classified as hemangiomas and vascular malfor-
Fig. 1- Female patient, 5 years old, with a congenital lesion in the lower lip. A. Initial clinical aspect of the le-
sion. B. Intralesional application of EO. C. The result after two applications. D. Final clinical aspect showing a 
complete regression of the lesion after six applications of EO.
Fig. 2. Male patient, 56 years old with a congenital lesion in the lower lip.  A. Clinical aspect in the first moment. 
B. After 1 application of EO. C. Complete regression of the lesion after 2 applications.
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Fig. 3. Female patient, 39 years old, with tongue lesion present for 15 years. A/B. Initial clinical aspect. C/D. Partial and functional 
result after two applications of EO.
mations and 7% were classified as varices. In contrast 
to the results of Corrêa et al. (2007) (4), varices of the 
ventral-lateral tongue were not included herein. 
The knowledge and treatment of oral vascular lesions 
are of great relevance to clinicians, because some rou-
tine procedures, such as surgical interventions, could 
lead to significant bleeding. Sclerotherapy treatment is 
generally performed in cases with risk of bleeding and 
compromise of aesthetic and/or physiological functions 
(such as speech and chewing). In this context, some im-
portant characteristics should be considered, including 
age of the patient, size, location and hemodynamics of 
the lesion (high or low blood flow). The choice of treat-
ment should be mainly based on these aspects and on 
the professional’s experience. In asymptomatic cases 
and in the absence of other disorders, clinical follow-up 
could be the best approach.
Sclerotherapy can provide satisfactory results in lesions 
of various sizes, especially in regions (face and lips) 
where other treatment options, such as surgery, could 
compromise the physiology and final aesthetic aspects. 
The technique contraindications involve uncontrolled 
diabetic patients, pregnant patients, lactating women 
and regions with secondary infection in which treat-
ment could cause oedema and bleeding in the damaged 
area. Complications, such as exacerbated tissue necro-
sis and undesired triggering of an anaphylactic reaction 
to the drug, were related to a larger injection volume 
than recommended (13,19,22).
Many substances have been used for vascular lesion 
sclerosis, including ethanolamine oleate (EO), sodium 
morrhuate, sodium tetradecyl sulfate, sodium psylli-
ate, hypertonic solution, 75% glucose, absolute alcohol, 
bleomycin and others (12,22,23). Studies have demon-
strated the effectiveness of these solutions; however, 
each of them has its own characteristics, indications and 
side effects (11,24). 
EO has been used for more than 60 years and, accord-
ing to the scientific literature, causes less damage to the 
connective tissue. The side effects of EO are limited and 
can be easily avoided when it is used appropriately (11-
13, 23). For these reasons and due to the facility of get-
ting this medication in Brazil, EO has been the scleros-
ing agent of choice in various services. The mechanism 
of action of EO involves an intra- and extravascular 
inflammatory response and fibrosis in the endothelium. 
The oleic acid portion causes an inflammatory reaction 
and also could activate coagulation, whereas the etha-
nolamine portion organizes the repression of the fibrin 
clot. Thus, the vascular lesion is replaced by fibrosis 
(25). These actions allow for a haemostatic balance and 
prevent bleeding after administration to vascular le-
sions (11,13,25).
Sclerotherapy may be considered a standard treatment 
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for oral vascular lesions; however, quite different proto-
cols were found in the scientific literature. Despite the 
simplicity and facility of the technique, the possibility 
of associated complications should not be ignored. The 
incidence and intensity of these complications depend 
directly on the technique used, the type and concentra-
tion of the sclerosing agent and the experience of the 
professional (11, 25-27).
Regarding the concentration of EO, Johan et al. (11) 
studied two different concentrations (1.25% and 2.5%) 
and found no difference in the final results and post-ap-
plication symptomatology. Likewise, Bonan et al. (25) 
reported that dilution of EO in distilled water resulted 
in no reduction of signs and symptoms. Also, dilution 
may have been responsible for reducing the action of the 
chemical agent in the vessel wall, resulting in a partial 
regression of lesions as described for two of the six le-
sions treated by these authors. 
The total number of applications, the response of the le-
sion and the success of the treatment varies and depends 
on different factors, such as the protocol used and the 
vascular flow (hemodynamic) of the lesion. Our experi-
ence shows that low-flow lesions, soft on palpation and 
with a slow return of blood volume after compression, 
often have a better and faster response to treatment and 
regress with fewer applications. On the other hand, the 
expected effect is not always successful for lesions with 
high blood flow.
In the present study, for lesions smaller than 1.0 cm, 0.3 
ml of EO was injected per session, often resulting in 
complete regression of the lesion with only one or two 
applications. Although 60% of cases required only one 
application of EO for a satisfactory result, in some le-
sions, more applications were necessary.
Even when higher doses are required, the intralesion-
al application of 5% EO can be used safely when the 
applied dose is compatible with the size of the lesion. 
Thus, the occurrence of significant complications, such 
as necrosis of adjacent tissue or any kind of systemic 
alterations, is avoided. Matsumoto et al. (28) suggested 
that doses lower than 1 ml of 5% EO can provide an 
important factor to prevent such complications. 
Furthermore, there are conflicting views with respect to 
the local anaesthetic application prior to the sclerosing 
agent injection. The use of no local anaesthesia can be 
justified by the maintenance of a painful sensation. This 
would allow the professional to stop the procedure when 
the sclerosing agent reached healthy tissues, thus avoid-
ing possible undesirable damage. However, the use of 
anaesthetics with vasoconstrictors can increases the 
action time of the drug in the lesion due to peripheral 
vasoconstriction. Also, the anaesthetic procedure may 
avoid immediate pain symptoms.
Of all the 90 cases retrieved in this study, only four were 
treated with a combination of sclerotherapy and posteri-
or surgery due to the size of the lesion. The surgical pro-
cedure was performed to remove the fibrous remnant of 
the lesion for the purpose of aesthetic and/or functional 
recovery. Two of these cases were previously published 
by our group (13).
Knowledge of the treatment options for oral vascular 
lesions is important for clinicians because they are rel-
atively common in clinical practice. Although sclero-
therapy is an acceptable and affordable treatment option 
for these lesions, several different sclerotherapy pro-
tocols were found in the scientific literature, showing 
variability in the concentration of the sclerosing agent, 
dose, and mode of application. This wide variety of 
techniques and protocols can difficult the choose of this 
particular treatment by clinicians. Herein, 43 cases of 
benign oral vascular lesions were treated with the same 
sclerotherapy protocol, which is used for more than 25 
years in our institution and showed successful results. 
Conclusions
Oral vascular lesions occurred over a wide age range 
with a female gender predominance. Clinically, these 
lesions appeared mainly as an asymptomatic nodular 
swelling, with variable size and frequently located in 
the lips, buccal mucosa and tongue. Sclerotherapy with 
EO is an affordable and acceptable treatment option 
showing effectiveness when properly used.
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